Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FOLFOXIRI tops doublets as bevacizumab backbone for mCRC

Publish date:: September 15, 2020

Key clinical point: Upfront treatment with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab “significantly and meaningfully” improves overall survival in metastatic colorectal cancer when compared with chemotherapy doublets plus bevacizumab.

Major finding: There was a 4.4-month increase in median overall survival and an 11.6% increase in estimated 5-year overall survival with FOLFOXIRI plus bevacizumab.

Study details: An analysis of 1,697 patients pooled from five clinical trials.

Disclosures: There was no external funding for the analysis, but some of the original trials were sponsored by Roche. The lead author disclosed ties with Roche and other companies.

Citation:

Cremolini C et al. J Clin Oncol. 2020 Aug 20. doi: 10.1200/JCO.20.01225.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,